THE Federal Court of Australia has fined Oxymed Australia Pty Ltd $2 million for advertising devices intended to administer hyperbaric oxygen therapy in breach of the Therapeutic Goods Act 1989.
The company's Director, Malcolm Hooper, has been fined a further $1 million for aiding, abetting, counselling or procuring the contraventions of the Act by Oxymed.
Oxymed was initially issued a $63,000 fine by the Therapeutic Goods Administration in Mar 2020.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Dec 21
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Dec 21
